Novel Tricyclic-α-alkyloxyphenylpropionic Acids: Dual PPARα/γ Agonists with Hypolipidemic and Antidiabetic Activity

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Journal of Medicinal Chemistry

• Publication date

  2002-01-23

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/JM010964G
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Exploring the antidiabetic efficacy of 3-mercapto-1,2,4-triazoles as potential inhibitors of α-amylase and α-glucosidase: A comprehensive review.

  2025cites this paper
• Chlorogenic Acid-Gut Microbiota Interactions: New Insights for Alleviating Chronic Diseases and Health Disorders.

  2025cites this paper
• Prediction of hepatic metabolic clearance in rats and dogs using long-term cocultured hepatocytes.

  2025cites this paper
• Synthesis, Biological Evaluation, Molecular Docking and Kinetic Investigation of New 2,4,5‐Trisubstituted Imidazole Derivatives as Antidiabetic Agents

  2023cites this paper
• Alkaloids from the rhizomes of Acorus calamus and their PPARα, PPARγ, and glucokinase-activating activities

  2021cites this paper
• Eight-Membered Rings With Two Heteroatoms 1,3

  2021cites this paper
• Structural, Hirshfeld, spectroscopic, quantum chemical and molecular docking studies on 6b′, 7′, 8′, 9′-Tetrahydro-2H,6′H-spiro[acenaphthylene-1,11′-chromeno [3,4-a]pyrrolizine]-2,6′(6a′H,11a′H)-dione

  2020cites this paper
• To Probe Full and Partial Activation of Human Peroxisome Proliferator-Activated Receptors by Pan-Agonist Chiglitazar Using Molecular Dynamics Simulations

  2020cites this paper
• The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.

  2020cites this paper
• Regioselective Synthesis of Carbazole‐Grafted Dispirothiapyrrolizine Derivatives via 1,3‐Dipolar Cycloaddition Strategy

  2019cites this paper
• Efficient catalyst-free tricomponent synthesis of new spiro[cyclohexane-1,4′-pyrazolo[3,4-e][1, 4]thiazepin]-7′(6′H)-ones

  2019cites this paper
• Discovery of a Novel Selective Dual Peroxisome Proliferator-Activated Receptor α/δ Agonist for the Treatment of Primary Biliary Cirrhosis.

  2019cites this paper
• Therapeutic applications of the versatile fatty acid mimetic WY14643

  2017cites this paper
• The application of molecular modelling in the safety assessment of chemicals: A case study on ligand-dependent PPARγ dysregulation.

  2017cites this paper
• Switching subtype-selectivity: Fragment replacement strategy affords novel class of peroxisome proliferator-activated receptor α/δ (PPARα/δ) dual agonists.

  2017cites this paper
• Synthesis, antimicrobial evaluation, and molecular docking studies of new tetrahydrocarbazole derivatives

  2016cites this paper
• Design and synthesis of novel Y-shaped barbituric acid derivatives as PPARγ activators.

  2016cites this paper
• PPARγ ligands and their therapeutic applications: a patent review (2008 – 2014)

  2015cites this paper
• Characterization of covalent bond formation between PPARγ and oxo-fatty acids.

  2015cites this paper
• Physical and Structural Characterization of Biofield Energy Treated Carbazole

  2015cites this paper
• Triglyceride-lowering agents.

  2014cites this paper
• Prospective QSAR-Based Prediction Models with Pharmacophore Studies of Oxadiazole-Substituted $$\alpha$$ α -Isopropoxy Phenylpropanoic Acids with Dual Activators of PPAR $$\alpha$$ α and PPAR $$\gamma$$ γ

  2014cites this paper
• Molecular Modelling Study of the PPARγ Receptor in Relation to the Mode of Action/Adverse Outcome Pathway Framework for Liver Steatosis

  2014cites this paper
• TFAA/H3PO4 mediated unprecedented N-acylation of carbazoles leading to small molecules possessing anti-proliferative activities against cancer cells.

  2014cites this paper
• Refinement of the Docking Component of Virtual Screening for PPAR

  2013cites this paper
• SAR and Computer-Aided Drug Design Approaches in the Discovery of Peroxisome Proliferator-Activated Receptor γ Activators: A Perspective

  2013cites this paper
• Prospective QSAR-based prediction models with pharmacophore studies of oxadiazole-substituted α-isopropoxy phenylpropanoic acids on with dual activators of PPARα and PPARγ

  2013cites this paper
• Find novel dual-agonist drugs for treating type 2 diabetes by means of cheminformatics

  2013cites this paper
• A tandem regression-outlier analysis of a ligand cellular system for key structural modifications around ligand binding

  2013cites this paper
• Targeting peroxisome proliferator-activated receptors (PPARs): development of modulators.

  2012cites this paper
• Protective effects of peroxisome proliferator‐activated receptor agonists on human podocytes: proposed mechanisms of action

  2012influential citation
• Effect of Oxime Ether Incorporation in Acyl Indole Derivatives on PPAR Subtype Selectivity

  2012cites this paper
• Design, synthesis and evaluation of novel zwitterionic compounds as PPARα/γ dual agonists (1).

  2012cites this paper
• 3D-QSAR study of tyrosine and propanoic acid derivatives as PPARα/γ dual agonists using CoMSIA

  2012cites this paper
• Docking, synthesis and anti-diabetic activity of novel sulfonylhydrazone derivatives designed as PPAR-gamma agonists.

  2012cites this paper
• Lipaemia, Inflammation and Atherosclerosis: Novel Opportunities in the Understanding and Treatment of Atherosclerosis

  2012cites this paper
• Novel Pharmacological Approaches to the Treatment of Type 2 Diabetes

  2012cites this paper
• The application of comparative molecular field analysis for the design of α-anilino substituted-3-phenyl propanoic acids as novel PPARα/γ dual ligands

  2012cites this paper
• Structural insight into the crucial role of ligand chirality in the activation of PPARs by crystallographic methods.

  2011cites this paper
• Biocatalysis: Synthesis of Key Intermediates for Development of Pharmaceuticals

  2011cites this paper
• Synthesis of Some Vanillin Semicarbazones and Evaluation of their Anti-Diabetic and Associated Hypocholestremic Activities.

  2011cites this paper
• High-density lipoprotein and coronary heart disease: current and future therapies.

  2010cites this paper
• Increased expression of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma in human atherosclerosis.

  2010cites this paper
• Dynamic correlation networks in human peroxisome proliferator-activated receptor-γ nuclear receptor protein

  2010cites this paper
• Virtual Screening as a Technique for PPAR Modulator Discovery

  2009cites this paper
• New 2-aryloxy-3-phenyl-propanoic acids as peroxisome proliferator-activated receptors alpha/gamma dual agonists with improved potency and reduced adverse effects on skeletal muscle function.

  2009cites this paper
• 4,4-Dimethyl-1,2,3,4-tetrahydroquinoline-based PPARalpha/gamma agonists. Part. II: Synthesis and pharmacological evaluation of oxime and acidic head group structural variations.

  2009cites this paper
• Structure‐Based Pharmacophore Screening for Natural‐Product‐Derived PPARγ Agonists

  2009cites this paper
• Identification of Druggable Hot Spots on Proteins and in Protein– Protein Interfaces

  2009cites this paper
• 4,4-Dimethyl-1,2,3,4-tetrahydroquinoline-based PPARalpha/gamma agonists. Part I: synthesis and pharmacological evaluation.

  2008cites this paper
• Omega-(2-Naphthyloxy) amino alkanes as a novel class of anti-hyperglycemic and lipid lowering agents.

  2008cites this paper
• Design, synthesis, and biological evaluation of novel constrained meta-substituted phenyl propanoic acids as peroxisome proliferator-activated receptor alpha and gamma dual agonists.

  2008cites this paper
• Sulindac Derivatives That Activate the Peroxisome Proliferator-activated Receptor γ but Lack Cyclooxygenase Inhibition

  2008cites this paper
• Synthesis and evaluation of a series of benzopyran derivatives as PPAR alpha/gamma agonists.

  2008cites this paper
• NSAIDs revisited: putative molecular basis of their interactions with peroxisome proliferator-activated gamma receptor (PPARgamma).

  2008cites this paper
• Dissociation of antihyperglycaemic and adverse effects of partial perioxisome proliferator-activated receptor (PPAR-gamma) agonist balaglitazone.

  2008cites this paper
• Synthesis, biological evaluation and molecular modeling studies of arylidene-thiazolidinediones with potential hypoglycemic and hypolipidemic activities.

  2007cites this paper
• Facile synthesis of optically pure (S)-3-p-hydroxyphenyllactic acid derivatives

  2007cites this paper
• Partial agonists activate PPARgamma using a helix 12 independent mechanism.

  2007cites this paper
• Ajulemic Acid, a Synthetic Nonpsychoactive Cannabinoid Acid, Bound to the Ligand Binding Domain of the Human Peroxisome Proliferator-activated Receptor γ*

  2007cites this paper
• Design of potent PPARα agonists

  2007cites this paper
• Evolution of Peroxisome Proliferator-Activated Receptor Agonists

  2007cites this paper
• Sulfonylureas and Glinides Exhibit Peroxisome Proliferator-Activated Receptor γ Activity: A Combined Virtual Screening and Biological Assay Approach

  2007cites this paper
• Peroxisome proliferator-activated receptor structures: ligand specificity, molecular switch and interactions with regulators.

  2007cites this paper
• Synthesis, Biological Evaluation, and Molecular Modeling Investigation of Chiral Phenoxyacetic Acid Analogues with PPARα and PPARγ Agonist Activity

  2007cites this paper
• Pomegranate flower: a unique traditional antidiabetic medicine with dual PPAR‐α/‐γ activator properties

  2007cites this paper
• Catalytic asymmetric epoxidation of alpha,beta-unsaturated esters with chiral yttrium-biaryldiol complexes.

  2007cites this paper
• Pharmacophore modeling and parallel screening for PPAR ligands

  2007cites this paper
• Selective PPAR Agonists for the Treatment of Type 2 Diabetes

  2006cites this paper
• Síntese, Modelagem Molecular e Atividade Hipoglicemiante de Novas Arilideno-Tiazolidinadionas

  2006cites this paper
• Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes.

  2006cites this paper
• 2‐{3‐[2‐(4‐Chlorophenyl)ethoxy]phenylthio}‐2‐methylpropanoic Acid: a Fibrate‐Like Compound with Hypolipidemic and Antidiabetic Activity

  2006cites this paper
• Peroxisome proliferator-activated receptors: how their effects on macrophages can lead to the development of a new drug therapy against atherosclerosis.

  2006cites this paper
• Insulin resistance – a common link between type 2 diabetes and cardiovascular disease

  2006cites this paper
• Recent Developments in the Treatment of Diabetes Type 2

  2006cites this paper
• Peroxisome Proliferator-Activated Receptor-α,γ-Agonist Improves Insulin Sensitivity and Prevents Loss of Left Ventricular Function in Obese Dyslipidemic Mice

  2006cites this paper
• Structure-based design of indole propionic acids as novel PPARα/γ co-agonists

  2006cites this paper
• Computational screening of phthalate monoesters for binding to PPARgamma.

  2006cites this paper
• Nondiabetic Mouse Model of Mixed Dyslipidemia , Activators Decrease Macrophage-Laden Atherosclerotic Lesions

  2005cites this paper
• Exploring the binding site structure of the PPAR gamma ligand-binding domain by computational solvent mapping.

  2005cites this paper
• Synthesis of PPAR agonist via asymmetric hydrogenation of a cinnamic acid derivative and stereospecific displacement of (S)-2-chloropropionic acid.

  2005cites this paper
• Design, synthesis and evaluation of carbazole derivatives as PPAR alpha/gamma dual agonists and antioxidants.

  2005cites this paper
• 2-Alkoxydihydrocinnamates as PPAR agonists. Activity modulation by the incorporation of phenoxy substituents.

  2005cites this paper
• Review: Vascular protective effects of peroxisome proliferator-activated receptor agonists

  2005cites this paper
• Structure-activity relationships of dimeric PPAR agonists.

  2005cites this paper
• Synthesis and biological evaluation of new clofibrate analogues as potential PPARα agonists

  2005cites this paper
• PPAR&agr;, but not PPAR&ggr;, Activators Decrease Macrophage-Laden Atherosclerotic Lesions in a Nondiabetic Mouse Model of Mixed Dyslipidemia

  2005cites this paper
• The dual PPARα/γ agonist, ragaglitazar, improves insulin sensitivity and metabolic profile equally with pioglitazone in diabetic and dietary obese ZDF rats

  2005cites this paper
• Emerging targets for diabetes

  2005cites this paper
• High speed development work by preparation of an "in-hand" library of NMR-quantified degradation products.

  2005cites this paper
• PPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis Published, JLR Papers in Press, October 16, 2004. DOI 10.1194/jlr.R400010-JLR200

  2004cites this paper
• Sphingosine 1-phosphate and lysophosphatidic acid receptors: agonist and antagonist binding and progress toward development of receptor-specific ligands.

  2004cites this paper
• Peroxisome proliferator-activated receptor gamma (PPARγ) ligands and their therapeutic utility

  2004cites this paper
• Synthetic ligands for peroxisome proliferator-activated receptor-α, review of the patent literature 2000 – 2003

  2004cites this paper
• Prediction of PPAR-α ligand-mediated physiological changes using gene expression profiles Published, JLR Papers in Press, December 16, 2003. DOI 10.1194/jlr.M300239-JLR200

  2004cites this paper
• A novel peroxisome proliferator-activated receptor alpha/gamma dual agonist demonstrates favorable effects on lipid homeostasis.

  2004cites this paper
• A novel oxyiminoalkanoic acid derivative, TAK-559, activates human peroxisome proliferator-activated receptor subtypes.

  2004cites this paper
• 3D QSAR studies on peroxisome proliferator-activated receptor γ agonists using CoMFA and CoMSIA

  2004cites this paper
• Expression in Vascular Cells Peroxisome Proliferator-Activated Receptors and Atherogenesis : Regulators of Gene

  2004cites this paper
• Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects: a 12-week, double-blind, placebo-controlled dose-ranging study with an open pioglitazone arm.

  2004cites this paper